Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
RCT-1100 by Recode Therapeutics for Primary Ciliary Dyskinesia: Likelihood of Approval
RCT-1100 is under clinical development by Recode Therapeutics and currently in Phase I for Primary Ciliary Dyskinesia. According to GlobalData,...